The 2018 edition of Financial Times “Innovative Lawyers” report recognized Sidley as a “Highly Commended” firm in the Managing Complexity & Scale subsection of the Legal Expertise section.
Financial Times praised Sidley for advising San Francisco-based biotech company Nektar Therapeutics in a strategic collaboration with Bristol-Myers Squibb for the development and commercialization of NKTR-214 — an immunotherapy product that is designed to stimulate the patient’s own immune system to fight cancer. Sidley advised Nektar Therapeutics on one of the largest upfront payments for a biotech product in pharma history in which Nektar entered into a global strategic development and commercialization collaboration with Bristol-Myers Squibb for the cancer drug. In addition to Bristol-Myers Squibb’s sizeable upfront payment of $1.85 billion dollars, Nektar also has the potential to receive approximately $1.8 billion in development, regulatory and commercial milestones.
Los Angeles and Palo Alto partner Joshua T. Hofheimer led the Sidley team in drafting and negotiating the strategic collaboration agreement, while Palo Alto partner Ruchun Ji led the equity investment and corporate governance work. They were supported by Dallas counsel Lauren G. Grau and associates Feifei Bian in Century City and Lori C. Trujillo in Los Angeles. Washington, D.C. partner Torrey Cope and Chicago partner Meenakshi Datta advised on the FDA and regulatory issues with support from associates Meghan F. Weinberg in Washington, D.C. Chicago senior counsel Marc E. Raven and Washington, D.C. handled the antitrust aspects of the transaction.
For full details of the deal, please click here.